<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000307</url>
  </required_header>
  <id_info>
    <org_study_id>BC-08071</org_study_id>
    <nct_id>NCT05000307</nct_id>
  </id_info>
  <brief_title>Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection</brief_title>
  <acronym>Coser</acronym>
  <official_title>Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In light of the current coronavirus disease 2019 (COVID-19) pandemic, the investigators want&#xD;
      to better study the immunological characteristics of Severe Acute Respiratory&#xD;
      Syndrome-Coronavirus 2 (SARS-CoV2) infections in adults. The investigators invite volunteers&#xD;
      to participate in a clinical study to better understand what happens after an infection with&#xD;
      SARS-CoV2. By collecting and analysing blood samples of people that were infected, the&#xD;
      investigators want to evaluate whether or not the participants had an adaptive immune&#xD;
      response with the producting of immunoglobulin. The investigators will evaluate the quality&#xD;
      of the antibodies and their neutralising capacity. In a selected patient group with strong&#xD;
      antibody response, the investigators will try to reproduce them in the lab after the&#xD;
      collection of a larger blood sample (max 72 mL) of, in case of insufficient B-cells, a&#xD;
      leucapheresis (after consent of the patient). These antibodies can be used in clinical trials&#xD;
      to evaluate whether the investigators can cure patients faster or prevent disease by the&#xD;
      utilisation of these antibodies.&#xD;
&#xD;
      Aside from the aforementioned information the investigators will also collect clinical data&#xD;
      such as: demographic information, medical history, routine lab results, radiographic imaging&#xD;
      and medication use.&#xD;
&#xD;
      After the completion of the study, the samples will be stored for 30 years with consent of&#xD;
      the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>(serial) blood samples in patients with proven SARS-CoV2</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralising capacity of naturally produced antibodies against SARS-CoV2</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Immune System Disorder</condition>
  <arm_group>
    <arm_group_label>Volunteers, infected with COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.</description>
    <arm_group_label>Volunteers, infected with COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of prior COVID-19 infection, documented by polymerase chain reaction (PCR) or&#xD;
             antibody testing (IgG based)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnancy at the time of screening&#xD;
&#xD;
          -  Patient is on immunosuppressive therapy or was treated with immunosuppressive therapy&#xD;
             during the last 6 months&#xD;
&#xD;
          -  Inability to give informed consent or absence of legal representative who can give&#xD;
             informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linos Vandekerckhove, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linos Vandekerckhove</last_name>
    <phone>+329332</phone>
    <phone_ext>3398</phone_ext>
    <email>Linos.Vandekerckhove@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linos Vandekerckhove, Prof. Dr.</last_name>
      <phone>+3293323398</phone>
      <email>linos.vandekerckhove@ugent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>Algemene Inwendige Ziekten</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>immunology</keyword>
  <keyword>SARS-CoV2</keyword>
  <keyword>Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

